Assessment
glofitamab
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic therapies (monotherapy, third line or later)
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relationsAssessment
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic therapies (monotherapy, third line or later)
Connected evidence
2 relations